接受异基因干细胞移植的骨髓纤维化患者的简易预后系统:CIBMTR/EBMT分析
基于CIBMTR队列623例接受异基因造血细胞移植的骨髓纤维化患者,用Cox多因素模型识别死亡预后因素并赋分,在欧洲EBMT队列623例中验证。年龄>50岁和HLA相合无关供者各1分,血红蛋白<100 g/L和不全相合无关供者各2分;低、中、高分组3年总生存分别为69%、51%和34%(P<.001)。评分可预测移植相关死亡率但不预测复发。
要点
- 年龄>50岁和HLA相合无关供者各赋1分,血红蛋白<100 g/L和不全相合无关供者各赋2分。
- 低分(1-2分)、中分(3-4分)、高分(5分)组3年总生存分别为69%、51%、34%(P<.001)。
- 评分升高可预测移植相关死亡率增加(P=.0017),但不预测复发(P=.12)。
核心结论
- 该评分系统在CIBMTR和EBMT两个大型队列中均可预测骨髓纤维化患者异基因造血细胞移植后的生存,便于临床医生与患者沟通移植结局。
研究设计与样本
- 研究纳入2000年至2016年间在美国CIBMTR队列中接受异基因造血细胞移植的623例骨髓纤维化患者,用Cox多因素模型识别死亡预后因素并赋分。
- 将赋分应用于欧洲EBMT队列中接受移植的623例患者进行验证。
主要发现
- 年龄>50岁(HR 1.39;95%CI 0.98-1.96)和HLA相合无关供者(HR 1.29;95%CI 0.98-1.7)与死亡风险增加相关,各赋1分。
- 移植时血红蛋白<100 g/L(HR 1.63;95%CI 1.2-2.19)和不全相合无关供者(HR 1.78;95%CI 1.25-2.52)各赋2分。
- 低分(1-2分)、中分(3-4分)和高分(5分)组3年总生存分别为69%(95%CI 61-76)、51%(95%CI 46-56.4)和34%(95%CI 21-49)(P<.001)。
- 评分升高可预测移植相关死亡率增加(P=.0017),但不预测复发(P=.12)。
- 在EBMT队列中,该评分可预测总生存(P<.001)和移植相关死亡率(P=.002),但不预测复发(P=.17)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To develop a prognostic model for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients undergoing allo-HCT between 2000 and 2016 in the United States (the Center for International Blood and Marrow Transplant Research [CIBMTR] cohort). A Cox multivariable model was used to identify factors prognostic of mortality. A weighted score using these factors was assigned to patients who received transplantation in Europe (the European Bone Marrow Transplant [EBMT] cohort; n = 623). Patient age >50 years (hazard ratio [HR], 1.39; 95% confidence interval [CI], 0.98-1.96), and HLA-matched unrelated donor (HR, 1.29; 95% CI, 0.98-1.7) were associated with an increased hazard of death and were assigned 1 point. Hemoglobin levels <100 g/L at time of transplantation (HR, 1.63; 95% CI, 1.2-2.19) and a mismatched unrelated donor (HR, 1.78; 95% CI, 1.25-2.52) were assigned 2 points. The 3-year overall survival (OS) in patients with a low (1-2 points), intermediate (3-4 points), and high score (5 points) were 69% (95% CI, 61-76), 51% (95% CI, 46-56.4), and 34% (95% CI, 21-49), respectively (P < .001). Increasing score was predictive of increased transplant-related mortality (TRM; P = .0017) but not of relapse (P = .12). The derived score was predictive of OS (P < .001) and TRM (P = .002) but not of relapse (P = .17) in the EBMT cohort as well. The proposed system was prognostic of survival in 2 large cohorts, CIBMTR and EBMT, and can easily be applied by clinicians consulting patients with MF about the transplantation outcomes.
引用
- Tamari R, McLornan DP, Ahn KW, et al. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis. Blood Adv. 2023. PMID: 37134306. doi:10.1182/bloodadvances.2023009886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。